PDF(Pubmed)
Abstract：
In a generation where advancements in research and understanding have led to remarkable achievements in medicine, it is still unfathomable that, after more than a century, the cause of schizophrenia is still a mystery. While antipsychotics, without a doubt, have brought on an exemplary revolution in the way psychiatric disorders are now treated, there are still imperative deficits that need to be addressed to ultimately enable individuals with schizophrenia to function normally in society. However, without a definite cause of schizophrenia, even though speculation has been made on its inflammatory and neurodegenerative nature, it has provided an unnecessary hindrance to finding further potential treatment modalities for these patients. Nevertheless, some trials are investigating potential adjunctive treatment regimens to antipsychotics, which can help achieve complete remission. Exploring these drugs will have significant implications for managing schizophrenia in future clinical practices. This systematic review was conducted between January 2012 to July 2022 according to Preferred Reporting Items for Systematic Review and Meta-Analysis guidelines to evaluate the safety and efficacy of ondansetron and simvastatin as adjunctive treatment to antipsychotics in adult patients with schizophrenia. This review included nine randomized controlled trials. Overall, both simvastatin and ondansetron, when used as adjunctive treatment in schizophrenia, appear to be safe. Ondansetron showed promising results, with all studies on this drug showing positive overall results on schizophrenia symptoms. On the other hand, simvastatin demonstrated mixed results, which can be attributed to the limited participants in the studies and the shorter duration of the trials. However, more extensive trials with uniform assessment tools are needed to demonstrate concrete evidence of the effectiveness of these drugs, whether alone or in combination with each other or perhaps another drug such as aspirin in schizophrenia.
摘要：
在研究和理解的进步导致医学取得显著成就的一代人中，仍然深不可测，一个多世纪后，精神分裂症的病因仍然是个谜。虽然抗精神病药，毫无疑问,在现在治疗精神疾病的方式上带来了堪称典范的革命，仍然有一些迫切需要解决的缺陷，以最终使精神分裂症患者能够在社会中正常运作。然而,没有明确的精神分裂症病因,尽管人们对其炎症和神经退行性性质进行了猜测，它为这些患者寻找进一步的潜在治疗方式提供了不必要的障碍。然而，一些试验正在研究抗精神病药物的潜在辅助治疗方案，可以帮助达到完全缓解。探索这些药物将对未来临床实践中精神分裂症的管理具有重要意义。本系统评价于2012年1月至2022年7月根据系统评价和荟萃分析指南首选报告项目进行，以评估昂丹司琼和辛伐他汀辅助治疗成年精神分裂症患者抗精神病药物的安全性和有效性。本综述包括9项随机对照试验。总的来说,辛伐他汀和昂丹司琼,当用作精神分裂症的辅助治疗时，看起来很安全.昂丹司琼显示了有希望的结果，对这种药物的所有研究都显示出精神分裂症症状的积极总体结果。另一方面,辛伐他汀表现出混合的结果，这可以归因于研究参与者有限和试验持续时间较短。然而,需要使用统一的评估工具进行更广泛的试验，以证明这些药物有效性的具体证据，无论是单独使用还是彼此联合使用，或者可能是另一种药物，如阿司匹林治疗精神分裂症。
